Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online before print January 7, 2009, doi:10.1212/01.wnl.0000340982.01727.6e)
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
Volume 72, Number 16, April 21, 2009
Right arrow Podcast
Right arrow Data Supplement
Right arrow Korean Translation
Right arrow JapaneseTranslation
Right arrow Italian Translation
Right arrow Correction (v72,p2059)
Right arrow All Versions of this Article:
01.wnl.0000340982.01727.6ev1
72/16/1378    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vaillancourt, D. E.
Right arrow Articles by Little, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vaillancourt, D. E.
Right arrow Articles by Little, D. M.
Related Collections
Right arrow All Imaging
Right arrow DWI
Right arrow Parkinson's disease/Parkinsonism
Right arrow Motor Control
Right arrow Basal ganglia
Right arrowRelated Article
NEUROLOGY 2009;72:1378-1384
© 2009 American Academy of Neurology

High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease

D. E. Vaillancourt, PhD, M. B. Spraker, BS, J. Prodoehl, PhD, PT, I. Abraham, D. M. Corcos, PhD, X. J. Zhou, PhD, C. L. Comella, MD and D. M. Little, PhD

From the Departments of Kinesiology and Nutrition (D.E.V., J.P., I.A., D.M.C.), Bioengineering (D.E.V., M.B.S., D.M.C., X.J.Z.), Neurology and Rehabilitation (D.E.V., D.M.L.), Physical Therapy (D.M.C.), Anatomy and Cell Biology (D.M.L.), Ophthalmology and Visual Sciences (D.M.L.), Psychology (D.M.L.), Neurosurgery (X.J.Z.), and Radiology (X.J.Z.), and Center for MR Research (X.J.Z.), University of Illinois at Chicago; and Department of Neurological Sciences (C.L.C.), Rush University Medical Center, Chicago, IL.

Address correspondence and reprint requests to Dr. David E. Vaillancourt, University of Illinois at Chicago, 1919 West Taylor, 650 AHSB, MC 994, Chicago, IL 60612 court1{at}uic.edu

Background: In the midbrain of patients with Parkinson disease (PD), there is a selective loss of dopaminergic neurons in the ventrolateral and caudal substantia nigra (SN). In a mouse model of PD, investigators have administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and found that measures derived using diffusion tensor imaging (DTI) were correlated with the number of dopamine neurons lost following intoxication.

Methods: Twenty-eight subjects (14 with early stage, untreated PD and 14 age- and gender-matched controls) were studied with a high-resolution DTI protocol at 3 Tesla using an eight-channel phase array coil and parallel imaging to study specific segments of degeneration in the SN. Regions of interest were drawn in the rostral, middle, and caudal SN by two blinded and independent raters.

Results: Fractional anisotropy (FA) was reduced in the SN of subjects with PD compared with controls (p < 0.001). Post hoc analysis identified that reduced FA for patients with PD was greater in the caudal compared with the rostral region of interest (p < 0.00001). A receiver operator characteristic analysis in the caudal SN revealed that sensitivity and specificity were 100% for distinguishing patients with PD from healthy subjects. Findings were consistent across both raters.

Conclusions: These findings provide evidence that high resolution diffusion tensor imaging in the substantia nigra distinguishes early stage, de novo patients with Parkinson disease (PD) from healthy individuals on a patient by patient basis and has the potential to serve as a noninvasive early biomarker for PD.

Abbreviations: DTI = diffusion tensor imaging; FA = fractional anisotropy; MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD = Parkinson disease; ROC = receiver operating characteristic; ROI = region of interest; SN = substantia nigra; UPDRS = Unified Parkinson’s Disease Rating Scale.


Supplemental data at www.neurology.org

Editorial, page 1374

e-Pub ahead of print on January 7, 2009, at www.neurology.org.

Supported by grants from the NIH (R01-NS-52318, R01-NS58487, R01-NS-28127, R01-NS-40902, R21-AG28662).

Disclosure: The authors report no disclosures.

Received July 10, 2008. Accepted in final form October 3, 2008.


Related Article

A new sensitive imaging biomarker for Parkinson disease?
Anthony E. Lang and David Mikulis
Neurology 2009 72: 1374-1375. [Full Text] [PDF]



This article has been cited by other articles:


Home page
NeurologyHome page
A. E. Lang and D. Mikulis
A new sensitive imaging biomarker for Parkinson disease?
Neurology, April 21, 2009; 72(16): 1374 - 1375.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by AAN Enterprises, Inc.